From: Legal access to medications: a threat to Brazil’s public health system?
Item | Number (%) |
---|---|
Insulin glargine - vial/cartridge/disposable pen | 3539 (6.3) |
Insulin aspart - vial/cartridge/disposable pen | 1849 (3.3) |
Methylphenidate - capsule/extended-release tablet | 1773 (3.1) |
Ranibizumab - ampoule | 1710 (3.0) |
Insulin lispro - vial/cartridge/disposable pen | 1565 (2.8) |
Acetylsalicylic acid (100–325 mg) - tablet/coated tablet/slow-release tablet | 1309 (2.3) |
Clopidogrel - tablet | 1224 (2.2) |
Levothyroxine (38–200 mcg) - tablet | 966 (1.7) |
Glucosamine + chondroitin - sachet/tablet | 968 (1.7) |
Cinacalcet hydrochloride - coated tablet | 906 (1.6) |
Boceprevir 200 mg - gelatine capsule | 844 (1.5) |
Simvastatin (5–80 mg) - tablet | 842 (1.5) |
Insulin detemir - cartridge/disposable pen | 834 (1.5) |
Omeprazole - tablet/capsule | 799 (1.4) |
Insulin glulisine - vial/cartridge/disposable pen | 801 (1.4) |
Sodium hyaluronate - injectable solution/vial | 771 (1.4) |
Pregabalin - capsule | 761 (1.4) |
Metformin + vildagliptin - capsule | 733 (1.3) |
Rosuvastatin (5–40 mg) - tablet | 730 (1.3) |
Zoledronic acid - injectable solution/vial | 675 (1.2) |
Subtotal: | 23,559 (41.9) |
TOTAL | 56,345 (100) |